期刊文献+

7-乙基-10-羟基喜树碱长循环脂质体的制备及药动学研究 被引量:11

Preparation of long-circulated liposome containing 7-ethyl-10-hydroxycamptothecin and its pharmacokinetic study
原文传递
导出
摘要 目的:研究7-乙基-10-羟基喜树碱长循环脂质体(Lip-SN38)的制备方法以及在大鼠体内的药动学。方法:采用两步合成法制备脂质体空间稳定膜材甲氧基聚乙二醇-磷脂酰乙醇胺(mPEG-PE);同时采用薄膜分散法制备Lip-SN38;用阳离子交换树脂微型小柱层析法分离游离药物和脂质体,紫外分光光度法测定包封率;HPLC法测定大鼠血浆中药物浓度。结果:Lip-SN38平均粒径<200 nm,药物包封率>90%;48 h只有<30%的药物体外释放;大鼠尾静脉注射Lip-SN38,剂量为10 mg.kg-1,与SN3-8溶液剂相比,t1/2β增加4.61倍。结论:采用薄膜分散法可制得包封率高、粒径小的脂质体,mPEG-PE修饰磷脂膜可增加Lip-SN38的t1/2β,延长药物在血中的循环时间。 Objective:To investigate the preparation of long-circulated liposome containing 7-ethyl-10- hydroxycamptothecin (Lip-SN38) and to observe its pharmacokinetics in rats. Methods: Methoxy-poly (ethylene glycol)-phosphatidylethanolamine was synthesized by a two-step process. Lip-SN38 was prepared by thin-film dis- persion method. Free drugs and liposomes were separated by cation exchange resin column chromatograph and drug entrapment efficiency was determined by ultraviolet-visible spectrophotometry (UV). HPLC method was established for the determination of SN38 concentration in plasma of rats. Results: Mean size of Lip-SN38 was 〈 200 nm and drug entrapment efficiency was 〉 90%. Drug released from Lip-SN38 in vitro was less than 30% within 48 h. Lip- SN38 was given to rats at 10 mg·kg^-1 by iv injection, t1/2β was 4.61 fold higher than SN-38 solution. Conclusion: By thin-film dispersion method,liposomes had been prepared with high entrapment efficiency and nanometer size. t1/2β of Lip-SN38 was increased and long circulation effects could be reached after modification of lipid membrane with mPEG-PE.
出处 《中国新药杂志》 CAS CSCD 北大核心 2008年第24期2132-2136,共5页 Chinese Journal of New Drugs
关键词 7-乙基-10-羟基喜树碱 甲氧基聚乙二醇-磷脂酰乙醇胺(mPEG—PE) 长循环脂质体 药动学 7-ethyl-10-hydroxycamptothecin( SN38 ) methoxy-poly ( ethylene glycol) -phosphatidylethanolamine (mPEG-PE) long-circulated liposome pharmacokinetics
  • 相关文献

参考文献4

二级参考文献22

  • 1Hanras C, Perrin J L. Gram-scale preparative HPLC of phospholipids from soybean lecithins [ J ]. J. Am. Oil Chem. Soc.,1991,(11) :804.
  • 2ZHANG Weinong, HE Haibo. Separation and purification of phosphatidylcholine and phosphatidylethanolamine from soybean degummed oil residues by using solvent extraction and column chromatography [ J ] . Journal of Chromatography ( B ),2003,798 : 323 - 331.
  • 3Gref R, Luck M, Quellec P, et al. Stealth corona-core nanoparticles surface modified by polyethylene glycol: influences of the corona PEG chain length and surface density and of the core composition on phagocytic uptake and plasma protein adsorption[J]. Colloid SurfB Biointerfaces, 2000,18(3-4): 301.
  • 4哈献文.羟基喜树碱疗效不高的原因[J].中国肿瘤,1995,4(12):31-31.
  • 5Peracchia MT, Vauthier C, Passirani C, et al. Complement consumtion by poly (ethylene glycol) in different conformations chemically coupled to poly (isobutyl 2-cyanoacrylate) nanoparticles [J]. Life Sci, 1997,61(5): 749.
  • 6Peracchia MT, Desmaele D, Couvreur P, et al. Synthesis of a novel (PEG cyanoacrylate-co-alkyl cyanoacrylate ) amphiphilic copolymer for nanoparticle technology [J]. Macromolecules, 1997,30(4): 846.
  • 7Peracchia MT, Harnisch S, Pinto-Alphandary H, et al. Visualization of in vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticles [J]. Biomaterials, 1999,20(14): 1269.
  • 8Peracchia MT, Vauthier C, Desmael D, et al. Pegylated nanoparticles from a novel methoxypolyethylene glycol cyanoacrylate-hexadecyl cyanoacrylate amphililic copolymer [J]. Pharm Res,1998,15(4): 550.
  • 9Li YP, Pei YY, Zhou ZH, et al. PEGylated polycyanoacrylate nanoparticles as tumor necrosis factor-alpha carriers [ J ]. J Controlled Release,2001,71(3): 287.
  • 10Li YP, Pei YY, Zhou ZH, et al. Stealth polycyanoacrylate nanoparticles as tumor necrosis factor-alpha carriers: pharmacokinetics and antitumor effects [J]. Biol Pharm Bull, 2001,24(6): 662.

共引文献36

同被引文献2049

引证文献11

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部